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ABSTRACT The diversity of OXA-48-like carbapenemases is continually expanding. In
this study, we describe the dissemination and characteristics of a novel carbapenem-
hydrolyzing class D -lactamase (CHDL) named OXA-436. In total, six OXA-436-producing
Enterobacteriaceae isolates, including Enterobacter asburiae (n  3), Citrobacter freundii
(n  2), and Klebsiella pneumoniae (n  1), were identiﬁed in four patients in the period
between September 2013 and April 2015. All three species of OXA-436-producing Enter-
obacteriaceae were found in one patient. The amino acid sequence of OXA-436 showed
90.4 to 92.8% identity to the amino acid sequences of other acquired OXA-48-like vari-
ants. Expression of OXA-436 in Escherichia coli and kinetic analysis of puriﬁed OXA-436
revealed an activity proﬁle similar to that of OXA-48 and OXA-181, with activity against
penicillins, including temocillin; limited or no activity against extended-spectrum cepha-
losporins; and activity against carbapenems. The blaOXA-436 gene was located on a con-
jugative 314-kb IncHI2/IncHI2A plasmid belonging to plasmid multilocus sequence
typing sequence type 1 in a region surrounded by chromosomal genes previously iden-
tiﬁed to be adjacent to blaOXA genes in Shewanella spp. In conclusion, OXA-436 is a
novel CHDL with functional properties similar to those of OXA-48-like CHDLs. The de-
scribed geographical spread among different Enterobacteriaceae and the plasmid loca-
tion of blaOXA-436 illustrate its potential for further dissemination.
KEYWORDS carbapenems
Ambler class D -lactamases constitute a large and diverse group of -lactamasesfrequently identiﬁed among clinically relevant Gram-negative bacteria either as
intrinsic chromosomally encoded -lactamases in certain species or as acquired
-lactamases associated with mobile genetic elements (1, 2). In Enterobacteriaceae, the
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acquired carbapenem-hydrolyzing class D -lactamases (CHDLs) have disseminated
widely since the ﬁrst identiﬁcation of OXA-48 in a Klebsiella pneumoniae isolate (3) and
have become the predominant carbapenemase type in many regions and countries (4).
To date, several closely related OXA-48-like variants (e.g., OXA-48, OXA-162, OXA-163,
OXA-181, OXA-204, OXA-232, OXA-244, OXA-245, OXA-247, OXA-370, and OXA-405)
have been identiﬁed in clinically relevant Enterobacteriaceae (1, 5, 6). The blaOXA-48-like
genes have been associated with different transposons formed by insertion sequences
(IS), such as IS1999 and ISEcp1, and for blaOXA-48, an association with IncL plasmids has
been described (1, 7, 8). Several studies have identiﬁed Shewanella spp., environmental
waterborne bacteria, to be the natural host of blaOXA-48-like genes (9–11).
The amino acid sequence similarities between acquired OXA-48-like variants are
high (97%). In general, the hydrolytic activities of OXA-48-like enzymes are similar to
those of other CHDLs, with activities against penicillins and carbapenems but no or
limited activity against extended-spectrum cephalosporins (2, 12). The activity against
carbapenems is variable but, in general, low, which, in the absence of additional
mechanisms (i.e., membrane permeability defects), often results in a carbapenem-
susceptible phenotype (12). Three variants, OXA-163, OXA-247, and OXA-405, deviate
from this general proﬁle, as they have clavulanic acid-inhibited activity against
extended-spectrum cephalosporins and even lower or negligible activity against car-
bapenems (6, 13, 14).
In this study, we describe a novel plasmid-mediated OXA-48 variant named OXA-436
initially discovered in an Enterobacter asburiae isolate recovered from a patient admit-
ted to a hospital in the Capital Region of Denmark and subsequently detected in
isolates from three other patients in Denmark, including other Enterobacteriaceae.
RESULTS AND DISCUSSION
Epidemiological setting and identiﬁcation of blaOXA-436. In September 2013, an
E. asburiae isolate (AMA 497) intermediate susceptible to meropenem was detected
from a urine sample from a patient (patient 1) (Table 1). In January 2014, a second E.
asburiae isolate (AMA 590), also intermediate susceptible to meropenem, was detected
from another patient (patient 2) at another hospital. Both isolates were positive for
carbapenemase production by the Carba NP test, and the phenotypic data indicated
the presence of a class D carbapenemase (see below). However, the isolates were
negative for blaOXA-48 by using previously described internal primers (3), as well as
negative for genes encoding other known carbapenemases, blaVIM, blaIMP, blaGIM,
blaSPM, blaSIM, blaNDM, and blaKPC, by PCR. In order to identify the carbapenemase, the
isolates were subjected to whole-genome sequencing (WGS), and the sequence data
(15) were analyzed using the ResFinder program (16), which indicated the presence of
a gene for a -lactamase with 88% nucleotide sequence similarity to blaOXA-181 (15).
Subsequent analysis of the nucleotide sequence and comparison of its nucleotide
sequence with the nucleotide sequences of the genes for other OXA-48-like variants
showed that it encoded a class D -lactamase with close similarity to other OXA-48-like
variants and was designated OXA-436 (Fig. 1). A new PCR for the detection of blaOXA-436
was subsequently developed and integrated into the PCR analysis of isolates suspected
of harboring a carbapenemase submitted to the Danish National Reference Laboratory.
Subsequently, four isolates recovered from two other patients in the period between
August 2014 and April 2015 were PCR positive for blaOXA-436 (Table 1).
In August 2014, a blaOXA-436 PCR-positive Citrobacter freundii isolate was detected
from a third patient (patient 3). During October and November 2014, a blaOXA-436-
positive K. pneumoniae isolate and a blaOXA-436 positive E. asburiae isolate were de-
tected from patient 3. In April 2015, a blaOXA-436-positive C. freundii isolate (AMA 948)
was recovered from a fourth patient (patient 4). The three E. asburiae isolates had highly
similar single nucleotide polymorphism (SNP) proﬁles (4 to 15 SNP differences), indi-
cating clonal spread. In contrast, the two C. freundii isolates belonged to two different
sequence types (STs; ST22 and ST65) and had very different SNP proﬁles (29,000 SNP
differences) (Table 1), indicating independent events of plasmid transfer.
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All six OXA-436-producing isolates were from clinical specimens and were from six
different hospitals (Table 1). Unfortunately, none of the hospitals screened the patients
by collection of a rectal swab sample for outbreak investigation. A retrospective analysis
of selected isolates submitted prior to the ﬁrst identiﬁcation of blaOXA-436 was per-
formed but revealed no blaOXA-436-positive isolates. None of the four patients with
OXA-436-producing isolates had recently traveled abroad, and the origin of the
blaOXA-436 gene remains unknown.
Phenotypic proﬁles and molecular characteristics of blaOXA-436-positive iso-
lates. The antimicrobial susceptibility proﬁles of the blaOXA-436-positive isolates are
summarized in Table 2. All isolates were resistant to penicillins (including high-level
resistance to temocillin), extended-spectrum cephalosporins, and aztreonam. Further-
more, all isolates were resistant to ertapenem but were either susceptible or interme-
diately susceptible to meropenem and imipenem. Nonsusceptibility to gentamicin,
tobramycin, ciproﬂoxacin, and trimethoprim-sulfamethoxazole was also observed.
All isolates retained susceptibility to ceftazidime-avibactam, colistin, amikacin, and
tigecycline, except for the C. freundii isolate, which was intermediately susceptible to
tigecycline. The non--lactam -lactamase inhibitor avibactam has been shown to be
a potent inhibitor of class A, class C, and certain class D enzymes (17). To assess the
inhibitory properties of avibactam on OXA-436, determination of the MICs of temocillin
and meropenem with and without avibactam were performed since OXA-48-like en-
zymes have limited or no activity against ceftazidime (12) and since the strains carried
multiple other -lactamases. For the clinical isolates, the additive inhibitory effect of 4
mg/liter avibactam reduced the temocillin MIC 16- to 32-fold and the meropenem MIC
16- to 64-fold. For the cloned OXA-436-producing Escherichia coli TOP10 isolate, the
temocillin MIC was reduced 16-fold; however, the lower endpoint of the test range for
meropenem allowed only a 2-fold MIC reduction to be observed. The results of
phenotypic synergy tests for -lactamase-mediated resistance were either inconclusive
or negative, with the exception of positive test results for extended-spectrum
-lactamases (ESBLs) (data not shown). No synergy between meropenem and boronic
acid, dipicolinic acid, or cloxacillin was observed. In addition, no zone diameter was
FIG 1 (A) Phylogenetic tree based on amino acid sequences showing the relationship of OXA-436, acquired OXA-48-like variants, and selected OXA-48-like
variants from Shewanella spp. The tree is rooted at the midpoint. OXA-48-like variants devoid of carbapenemase activity are indicated with asterisks. (B)
Alignment of the amino acid sequence of OXA-436 with the amino acid sequences of selected OXA-48-like variants. Conserved motifs are shaded in black. The
secondary structural elements of OXA-48 are indicated above the sequences.
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observed with temocillin, indicating the presence of an OXA-48-like carbapenemase
(18). All isolates were Carba NP test positive, illustrating the usefulness of this method
for the detection of novel carbapenemases. Although some studies have reported
problems with the low sensitivity of this test for OXA enzymes (19, 20), the enzyme
activity of OXA-436 was sufﬁcient for a positive Carba NP test result, and positive
reactions were observed in 30 min. Similarly, positive test results were also obtained
for all six study isolates by a novel immunochromatographic test (OXA-48 K-SeT; Coris
BioConcept) for the detection of OXA-48-like enzymes. This showed that the monoclo-
nal anti-OXA-48 antibodies incorporated in this lateral ﬂow-based test also bind to the
OXA-436-containing conjugate.
Genetic context of blaOXA-436. The identiﬁcation of blaOXA-436 in different species,
including the identiﬁcation of three different blaOXA-436-positive species from the same
patient (patient 3), indicated that blaOXA-436 is plasmid borne and that transfer can
occur in vivo. Further, the identiﬁcation of a common set of acquired resistance genes
(Table 1) among the isolates indicated colocalization on the same mobile genetic
element. Replicon identiﬁcation using the PlasmidFinder web tool also showed the
presence of IncHI2 and IncHI2A replicons in all strains. In vitro plasmid transfer exper-
iments supported the plasmid localization of blaOXA-436, as transconjugants were
obtained from three donor strains (C. freundii AMA 754, K. pneumoniae AMA 782, and
E. asburiae AMA 810). This was conﬁrmed by combined single-molecule real-time
(SMRT; PacBio) and MiSeq (Illumina) sequencing to generate a circular plasmid (desig-
nated pOXA436) genome of 314,137 bp (Fig. 2A) harboring blaOXA-436. pOXA436 were
found to be an IncHI2 plasmid belonging to ST1 according to the plasmid double-locus
sequence typing scheme for IncHI2 plasmids (21). Comparison of pOXA436 with other
IncHI2 plasmids showed the presence of the common backbone found in other IncHI2
plasmids (see, e.g., references 21, 22, 23, 24), including the replicon IncHI2, transfer
regions Tra1 and Tra2, a partitioning system, and regions conferring resistance to heavy
metals (tellurite, mercury, and arsenic). IncHI2 plasmids have previously been associ-
ated with a large number of various antibiotic resistance genes, including genes for
carbapenemases, such as blaVIM, blaIMP, and blaNDM (21, 25). In pOXA436, the antibiotic
resistance genes were located in two separate regions of the plasmid (Fig. 2A). In
contrast to the neighboring genetic structures of blaOXA-48-like genes identiﬁed in
Enterobacteriaceae, which are closely associated with IS elements, such as IS1999 and
ISEcp1 (1), the blaOXA-436 gene was located in a region of 7,300 bp surrounded by
chromosomal genes previously identiﬁed to be adjacent to blaOXA genes in Shewanella
(9). This region included an open reading frame encoding a hypothetical protein and
the sprT gene, encoding a protein of unknown function, upstream of blaOXA-436.
Downstream of blaOXA-436, a gene encoding a putative LysR-type transcriptional regu-
lator was followed by a truncated acc gene encoding a carbamoyl phosphate synthase.
Overall, this region showed high nucleotide sequence similarity (96%) with the chro-
mosomal region in Shewanella sp. strains MR-4 and MR-7, isolated from the Black Sea;
Shewanella sp. strain ANA-3, isolated from arsenic-treated wood in a brackish estuary in
the United States (26); and a clinical Shewanella bicestrii sp. nov. isolate, JAB-1 (GenBank
accession number CP022358). The species of strains MR-4, MR-7, and ANA-3 have not
been determined, but genome analysis indicates that these could represent new
Shewanella species (26). Interestingly, a novel OXA-48-like enzyme, OXA-535, with
98.9% amino acid sequence identity to OXA-436 was identiﬁed in Shewanella bicestrii
sp. nov. strain JAB-1 (27), suggesting that this might be the original host and that
blaOXA-535 is the progenitor of blaOXA-436. The exact mechanism behind the mobilization
of the blaOXA-436 region onto the pOXA436 plasmid is unclear. However, two IS91
family-like IS elements (ISCR1) were identiﬁed upstream of the blaOXA-463 region and
one was identiﬁed downstream of the blaOXA-463 region, and these elements could
have been involved in the mobilization of the blaOXA-436 region onto the pOXA436
plasmid (Fig. 2B). The transposase genes of all three IS91-like/ISCR1 elements were
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FIG 2 (A) Circular map of pOXA436 (GenBank accession number KY863418) drawn using CGView (47). The two outer circles show predicted open reading frames, with
selected genes indicated according to gene function (see the key for the color scheme). The next four circles show homology to other IncHI2 plasmids: R478 (GenBank
accession number BX664015), pH11 (GenBank accession number CP013215), pK29 (GenBank accession number EF382672), and pEC_IMP (GenBank accession number
EU855787). (B) Linear representation of the genetic structure surrounding the blaOXA-436 region in pOXA436. Arrows represent open reading frames and the direction
of transcription. Horizontal dotted lines mark the boundaries of the region with a high level of identity to Shewanella isolates MR-4 (GenBank accession number
CP000446), MR-7 (GenBank accession number CP000444), and ANA-3 (GenBank accession number CP000469) and S. bicestrii sp. nov. JAB-1 (GenBank accession number
CP022358). The nucleotide positions of the fragment in relation to the pOXA436 sequence are indicated.
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identical at the amino acid level, and their amino acid sequences were identical to the
amino acid sequence with GenBank accession number WP_000050481.
The antimicrobial susceptibility of one representative transconjugant (AMA 1292)
showed the expected proﬁle according to the resistance genes present on pOXA436
(Table 2).
Characterization of OXA-436. Analysis of the OXA-436 amino acid sequence
showed that, in contrast to the limited differences (97.4% amino acid sequence
similarity) between previously described acquired OXA-48-like variants, the amino acid
sequence of OXA-436 showed only 90.4 to 92.8% similarity to the amino acid sequences
of the acquired OXA-48-like variants (Fig. 1). However, a greater amino acid sequence
similarity (97.7 to 98.5%) to the amino acid sequences of blaOXA-48-like genes from
Shewanella isolates MR-4, MR-7, ANA-3, and JAB-1 (GenBank accession numbers
CP000446, CP000444, CP000469, and CP022358, respectively) was observed (9). This
may indicate that the Shewanella species that is the natural host of blaOXA-436 is
different from the Shewanella species that is the natural host of blaOXA-48 and
blaOXA-181, which has been identiﬁed to be Shewanella xiamenensis (9, 11). Subsequent
cloning and expression of blaOXA-436, blaOXA-48, and blaOXA-181 in E. coli TOP10 showed
that OXA-436 produced the characteristic proﬁle of OXA-48-like carbapenemases (12),
resulting in a signiﬁcant increase (2-fold) in the MICs of penicillins and carbapenems
and no signiﬁcant change in the MICs of extended-spectrum cephalosporins and
monobactams (aztreonam) (Table 2). The values of the kinetic parameters determined
were also in broad agreement with the in vitro susceptibility data (Table 2) and were
similar to the previously determined values of the kinetic parameters of OXA-48 (3, 28,
29) and OXA-181 (12) (Table 3). As shown for other OXA-48-like carbapenemases, the
activity of OXA-436 against extended-spectrum cephalosporins was limited. Mea-
surable activity of OXA-436 against ceftazidime (kcat/Km, 0.047 M1 · s1) was
observed, and this activity was slightly higher than that initially described for
OXA-48 (kcat/Km, 0.001 M1 · s1) (3), mainly due to the lower Km. Activity against
ceftazidime has been described for OXA-48-like variants, such as OXA-163 and
OXA-232 (12). However, for OXA-163 and OXA-232, this has been at the expense of
reduced activity against carbapenems and temocillin (OXA-232) (12). As the hydro-
lytic activity against ceftazidime did not result in a change in the MIC for E. coli
TOP10 in the susceptibility assay (Table 2), this could indicate that the activity is
observed only in vitro or that the in vitro activity is too low to contribute to activity
in vivo. In contrast to previously published kinetic data, the kinetic assay for
OXA-436 was performed in the presence of sodium bicarbonate, as CO2 is required
for N-carboxylation of the catalytic lysine (30). However, experiments without
sodium bicarbonate showed similar results (data not shown), with measurable
hydrolytic activity against ceftazidime being found. Investigation of the changes in
the amino acid composition of OXA-436 in light of the three-dimensional structure
TABLE 3 Kinetic parameters of OXA-436 compared to OXA-48 and OXA-181
Subtrate
Km (M) kcat (s1) kcat/Km (M1 · s1)
OXA-436 OXA-48a OXA-181b OXA-436 OXA-48a OXA-181b OXA-436 OXA-48a OXA-181b
Benzylpenicillin 200 100 79 90 900 100 446 444 4.5 5.6 5.0
Ampicillin 5 1 395 170 600 40 955 218 120 2.4 1.3
Temocillin 200 100 45 60 3 1 0.3 0.3 0.015 0.0066 0.005
Cefotaxime 130 20 190 1000 6 0.4 10 62 0.046 0.06 0.013
Ceftazidime 150 50 5100 NHc 7 1 4 NDd 0.047 0.001 ND
Imipenem 20 1 13 13 6 0.2 4.8 7.5 0.3 0.37 0.55
Meropenem 3 1 11 70 0.14 0.01 0.07 0.1 0.047 0.0062 0.0015
Ertapenem 160 60 100 100 0.4 0.05 0.13 0.2 0.0025 0.0013 0.002
aKinetic parameters for OXA-48 are from Docquier et al. (28), except for those for benzylpenicillin, which are from Antonelli et al. (29), and cefotaxime-ceftazidime,
which are from Poirel et al. (3).
bKinetic parameters for OXA-181 are from Oueslati et al. (12).
cNH, no detectable hydrolysis.
dND, not determined.
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of OXA-48 clearly showed that most mutations were at the protein surface, as would
be expected for random mutations, because the inner core of enzymes is more
conserved (31). The two buried residues Ile226 (similar to OXA-48 Val226) and
Thr237 (Met237 in OXA-48), localized to the 7 sheet (28), are common residues in
 sheets. Since the majority of the changes are localized at the surface in the
three-dimensional structure of OXA-48, it seems likely that there would be no major
changes to the overall fold of the OXA-436 structure compared to that of the
OXA-48 structure. We believe that this is reﬂected in the similar functional charac-
teristics of the two enzymes (Table 3). We are currently determining the crystal
structure of OXA-436.
Conclusions. OXA-48 and OXA-48-like variants have become the dominant carbap-
enemases among Enterobacteriaceae in several regions and epidemiological settings
(4). In this study, we identiﬁed a novel OXA-48-like variant named OXA-436 with higher
amino acid sequence divergence from the currently identiﬁed OXA-48-like variants than
the other OXA-48-like variants, whose sequences are closely related. Despite this
divergence, OXA-436 shows broadly the same functional properties as other OXA-48-
like variants with carbapenemase and penicillinase activity. The high degree of amino
acid sequence similarity of OXA-436 with the amino acid sequences of OXA-48-like
variants in members of the genus Shewanella whose species have so far not been
determined further underlines the importance of species of this genus as the reservoir
for OXA-48-like variants. The identiﬁcation of blaOXA-436 in three different Enterobacte-
riaceae species and four patients indicates the potential for further dissemination. The
increased divergence of OXA-48-like variants complicates molecular-based detection
and shows the importance of phenotypic and biochemical methods for the detection
of carbapenemases.
MATERIALS AND METHODS
Bacterial strains. Six clinical isolates from four hospitalized patients were submitted to the Reference
Laboratory for Antimicrobial Resistance and Staphylococci at the Statens Serum Institut in Copenhagen,
Denmark, as part of the national surveillance for carbapenemase-producing organisms (approved by the
Danish Data Protection Agency [no. 2015-57-0102]). Species identiﬁcation was initially performed using
matrix-assisted laser desorption ionization–time of ﬂight mass spectrometry (MALDI-TOF MS; Bruker
Daltonik, Bremen, Germany) and subsequently using the whole-genome sequence data described below.
Escherichia coli TOP10 (Invitrogen, CA, USA) was used as the host strain for the cloning and expression
of blaOXA-436, blaOXA-48, and blaOXA-181. E. coli J53A3R was used for mating experiments. blaOXA-48 and
blaOXA-181 were obtained from previously described strains (32).
Antimicrobial susceptibility testing, phenotypic analysis, and initial PCR screening. MIC deter-
minations were performed by broth microdilution using in-house-designed premade Sensititre microtiter
plates (Trek Diagnostic Systems/Thermo Fisher Scientiﬁc, East Grinstead, UK). The MICs of the combina-
tion of temocillin (Eumedica, Basel, Switzerland) and meropenem (Hospira, Lake Forest, IL, USA) with
avibactam (AstraZeneca, Cheshire, UK) were determined using the CLSI broth microdilution MIC meth-
odology (33). Susceptibility patterns were interpreted according to the clinical breakpoints deﬁned by
EUCAST (version 7.1; http://www.eucast.org/clinical_breakpoints/). Combination gradient strips and discs
for phenotypic detection of extended-spectrum -lactamases (ESBLs; Becton Dickinson, Sparks, MD,
USA/Lioﬁlchem), AmpC -lactamases (Rosco Diagnostica, Taastrup, Denmark/Lioﬁlchem), and carbapen-
emases (Rosco Diagnostica) were performed according to the manufacturers’ instructions. The Carba NP
test was performed as previously described (34), and the OXA-48 K-SeT test (Coris BioConcept, Gembloux,
Belgium) was performed according to the manufacturer’s instructions. Initial PCR screening for
carbapenemase-encoding genes was performed using assays previously described for the detection of
blaVIM, blaIMP, blaGIM, blaSPM, blaSIM, blaNDM, blaKPC, and blaOXA-48 (3, 35, 36).
Whole-genome sequencing (WGS) and sequence analysis. Genomic DNA was extracted from
carbapenemase-producing isolates using a DNeasy blood and tissue kit (Qiagen, Hilden, Germany).
Fragment libraries were constructed using a Nextera kit (Illumina, Little Chesterford, UK), followed by
251-bp paired-end sequencing (MiSeq; Illumina), according to the manufacturers’ instructions. Paired-
end sequence data were assembled using CLCbio’s Genomics Workbench (version 8.0; Qiagen, Aarhus,
Denmark).
The sequence reads from the Citrobacter freundii and Enterobacter asburiae isolates were aligned
against the reference genomes of C. freundii CFNIH1 (GenBank accession number NZ_CP007557) and E.
asburiae L1 (GenBank accession number NZ_CP007546), respectively, using the short-read alignment
component of the Burrows-Wheeler aligner (BWA) (37). Using the Northern Arizona SNP Pipeline
(http://tgennorth.github.io/NASP/), identiﬁcation of SNP variants was performed using the GATK Uni-
ﬁedGenotyper with ﬁltering set to remove positions with less than 10 coverage and 90% unambig-
uous variant calls after positions within duplicated regions of the reference sequence were removed
using the NUCmer program (38). Phylogenetic analysis of the identiﬁed SNPs was performed using
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maximum parsimony implemented in MEGA (version 6.0.6) software (39). Comparison of the sequences
was performed using CLCbio’s Genomics Workbench (version 8.0; Qiagen).
The web servers of ResFinder (version 2.1), PlasmidFinder (Enterobacteriaceae) (version 1.2), pMLST
(IncHI2; version 1.4), and MLST (version 1.7) at http://www.genomicepidemiology.org/ were used to
identify acquired antimicrobial resistance genes, plasmid replicon types, the plasmid multilocus se-
quence types (pMLST), and multilocus sequence types (MLST) from the assembled WGS data, respectively
(16, 40, 41). For resistance genes, a threshold of 100% identity was used for the genes encoding
-lactamases, and 98% identity was used for all other genes. A lower identity threshold (60%) was initially
used to search for putative novel -lactamase genes.
Species identiﬁcation using WGS data for the Enterobacter isolates was performed using phylogenetic
analysis of fragments of the two housekeeping genes rpoB and hsp60 as described by Paauw et al. (42).
Comparisons of the sequences of contigs containing blaOXA-436 were done using BLAST analysis (https://
blast.ncbi.nlm.nih.gov/Blast.cgi). The amino acid sequences of acquired OXA-48-like variants and selected
OXA-48-like variants were obtained from the NCBI Bacterial Antimicrobial Resistance Reference Gene
Database (BioProject accession number PRJNA313047). Alignment and construction of a phylogenetic
tree of OXA-48-like variants were done in the RAxML (version 8.2.8) program (43) using the MAFTT
(version 7.305b) program (44) with a bootstrap of 100 replicates. A structural amino acid sequence
alignment was created using the ESpript (version 3.0) program (http://espript.ibcp.fr/ESPript/ESPript/)
(45).
A complete plasmid DNA sequence was obtained from a genome extracted from E. asburiae AMA 497
(Table 1) using a Genomic-tip 500/G kit (Qiagen, Hilden, Germany), which was used to prepare a 20-kb
library for sequencing on a Paciﬁc Biosciences RS II instrument using P6-C4 chemistry with a 360-min
moving time on one single-molecule real-time (SMRT) cell (Paciﬁc Biosciences, Menlo Park, CA) to
generate 90,579 reads for a total of 1,503 Mb. Initial scaffolding was performed using HGAP (version 3)
(SMRT analysis software, version 2.3.0; Paciﬁc Biosciences) to give an average base coverage of 133. The
paired-end MiSeq data from AMA 497 described above were used for error correction and ﬁnalization of
the sequencing data. The assembled plasmid sequence was annotated with the Prokka software tool (46)
and manually curated for accuracy. A circular plasmid map was drawn using the CGView program (47).
Cloning, expression, and puriﬁcation. For expression and puriﬁcation of OXA-436, blaOXA-436 was
ampliﬁed using forward (5=-ATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCGTGCGTTAGCCTTA-3=)
and reverse (5=-CTTTGTTAGCAGCCTCGAATCACTAAGGAATAATTTTTTCCTGTTTCAG-3=) primers. The prim-
ers contain overlaps with pDEST17 (Invitrogen, CA, USA), and blaOXA-436 with the signal peptide was
cloned into pDEST17 using restriction-free cloning as previously described (48). The puriﬁed plasmid was
transformed into E. coli BL21 Star(DE3)pRARE cells (49) and expressed in ZYP5052 (50) cultures containing
100 g/ml ampicillin and 34 g/ml chloramphenicol. OXA-436 was isolated from the periplasm and
puriﬁed by anion-exchange chromatography as described previously (51). The protein identity was
conﬁrmed by mass spectrometry.
For functional resistance proﬁle analysis, cloning and expression of blaOXA-436, blaOXA-48, and blaOXA-181
in an isogenic E. coli background were performed using a pCR-BluntII-TOPO cloning kit (Invitrogen, CA,
USA). PCR fragments containing the entire sequences of the blaOXA genes were obtained by PCR using
Phusion high-ﬁdelity PCR Mastermix with high-ﬁdelity buffer (New England BioLabs, MA, USA) and the
following primer pairs: OXAP18-15A (5=-TTTATTGCATTAGGCAAGGG-3=)/OXAP18-15B (5=-TACACAAATGC
GCCGCTAACC-3=) for blaOXA-436 and preOXA-48A/preOXA-48B for blaOXA-48 and blaOXA-181 (13). The PCR
products were run on a 1% agarose gel (Lonza, Rockland, ME, USA) and gel puriﬁed using a NucleoSpin
gel and PCR cleanup kit (Macherey-Nagel, Düren, Germany) before cloning into the pCR-BluntII-TOPO
vector and transformation into E. coli TOP10 according to the manufacturer’s instruction (Invitrogen, CA,
USA). Transformants were selected on Luria-Bertani (LB) agar plates (Becton Dickinson) containing 50
mg/liter kanamycin (Sigma-Aldrich, St. Louis, MO, USA). Veriﬁcation of the cloned DNA insert was
performed by PCR and Sanger sequencing (BigDye, version 3.1, technology; Applied Biosystems, CA, USA)
using M13 forward (5=-GTAAAACGACGGCCAG-3=) and reverse (5=-CAGGAAACAGCTATGAC-3=) primers.
Kinetic analysis. All kinetic experiments for -lactam substrates were performed using UV spectros-
copy with a SpectraMax M2e spectrophotometer (Molecular Devices) at 25°C in triplicate in 100 mM
sodium phosphate buffer (Sigma-Aldrich, St. Louis, MO, USA), pH 7.0, supplemented with 50 mM sodium
bicarbonate (Merck Millipore, Darmstadt, Germany) and 0.2 mg/ml bovine serum albumin (Sigma-
Aldrich, St. Louis, MO, USA) (30). Hydrolysis measurements were performed with ampicillin (Δ235 
820 M1 cm1, 0.4 to 112.5 M [Sigma-Aldrich]; 0.1 nM OXA-436), benzylpenicillin (Δ235  775 M1
cm1, 222 to 3,000 M [Panpharma]; 0.1 nM OXA-436), cefepime (Δ260  10,000 M1 cm1, 14 to 462
M [European Pharmacopoeia Reference Standards]; 1 nM OXA-436), cefotaxime (Δ260  7,500 M1
cm1, 2.5 to 217.3 M [Tokyo Chemical Industry Co., Ltd.]; 1 nM OXA-436), ceftazidime (Δ260  9,000
M1 cm1, 3.9 to 500 M [Sigma-Aldrich]; 1 nM OXA-436), ertapenem (Δ300  6,920 M1 cm1, 7.8
to 1,000 M [Merck Sharp & Dohme]; 5 nM OXA-436), imipenem (Δ300 nm  9,000 M1 cm1, 0.4 to
50 M [European Pharmacopoeia Reference Standards]; 1 nM OXA-436), meropenem (Δ300  6,500
M1 cm1, 0.4 to 50 M [Sigma-Aldrich]; 5 nM OXA-436), and temocillin (Δ235  660 M1 cm1, 3.9
to 500 M [Eumedica Pharmaceuticals]; 5 nM OXA-436). Kinetic parameters were determined by
nonlinear regression of the steady-state velocities as a function of the substrate concentrations using the
Michaelis-Menten equation in Prism (version 6) software (GraphPad Software, CA, USA).
Design of blaOXA-436 PCR. Primers for the speciﬁc PCR detection of a 672-bp blaOXA-436 fragment,
blaOXA-436 forward (5=-TCGGCTGTGTTGATGGTGA-3=) and blaOXA-436 reverse (5=-GTCATCCAGTTCGATCCA-
3=), were designed using CLCbio’s Main Workbench (version 7.5.1; Qiagen). A Qiagen multiplex PCR kit
(Qiagen, Venlo, the Netherlands) was used for master mix preparation, and PCR conditions were initial
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heat activation at 94°C for 15 min and 26 cycles of denaturation for 30 s at 94°C, annealing for 90 s at
58°C, and elongation for 60 s at 72°C, followed by a ﬁnal elongation step of 10 min at 72°C.
In vitro conjugation experiments. In vitro conjugation experiments were performed using the
sodium azide-resistant strain E. coli J53A3R as the recipient and E. asburiae AMA 497, C. freundii AMA 754,
K. pneumoniae AMA 782, and E. asburiae AMA 810 as the donor strains. The recipient and donor strains
were grown overnight in 50 ml Luria Bertani (LB) broth (with shaking at 120 rpm and 35°C). For the
donor strains, LB broth was supplemented with 1 mg/liter ceftriaxone (Roche, Hvidovre, Denmark).
After overnight incubation, 100 l of the culture was added to 10 ml fresh LB broth and regrown
without shaking at 35°C to a turbidity equivalent to that of an approximately 1.0 McFarland
standard. Donor and recipient cells were subsequently mixed at a 1:1 ratio. Two hundred microliters
of the mixed culture was added onto three separate 0.45-m-pore-size nitrocellulose MF membrane
ﬁlters (Merck Millipore Ltd., Cork, Ireland) placed on 5% blood agar plates (SSI Diagnostica, Hillerød,
Denmark), and the plates were incubated overnight at 35°C. In addition, the mixed culture was left
for liquid mating overnight at both room temperature and 35°C. After overnight incubation, the
membrane ﬁlters were transferred to 5 ml 0.9% saline and vortexed. One hundred microliters of the
0.9% saline suspension with membrane ﬁlters and 100 l of the resulting liquid mating culture were
spread on LB agar plates supplemented with either 2 mg/liter ceftriaxone plus 100 mg/liter sodium
azide (SSI Diagnostica, Hillerød, Denmark) or 8 mg/liter gentamicin (Sandoz, Holzkirchen, Germany)
plus 100 mg/liter sodium azide. After overnight incubation at 35°C, putative transconjugant colonies
were subcultured, and the successful transfer of blaOXA-436 was subsequently conﬁrmed by PCR as
described above combined with species identiﬁcation using MALDI-TOF MS (Bruker Daltonik). For
conﬁrmatory purposes, one representative transconjugant per donor-recipient combination was
subjected to WGS analysis as described above.
Accession number(s). WGS data from the isolates have been deposited at the National Center for
Biotechnology Information (NCBI) under BioProject PRJNA297498, and the annotated sequence of
plasmid pOXA436 has been deposited in GenBank under accession number KY863418. Annotated
contigs harboring blaOXA-436 have been deposited in GenBank (GenBank accession numbers KT959103 to
KT959108).
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